Related Experiment Video

Updated: Jul 15, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

A review of first-line treatment for small-cell lung cancer

Nevin Murray1, Andrew T Turrisi

  • 1University of British Columbia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. nmurray@bccancer.bc.ca

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|April 6, 2007
PubMed

Insights

Small-cell lung cancer (SCLC) research is crucial despite its lower incidence. Current chemotherapy offers no clear improvement over etoposide and cisplatin, but radiotherapy innovations show promise for limited-stage SCLC.

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Medical Research

Background:

  • Small-cell lung cancer (SCLC) constitutes a smaller fraction of lung cancer cases but remains a significant cause of cancer mortality.
  • Despite advances, current chemotherapy regimens have not surpassed the standard of care for SCLC.

Purpose of the Study:

  • To review the current state of clinical and basic research in small-cell lung cancer.
  • To highlight the efficacy of established chemotherapy and emerging radiotherapy strategies.

Main Methods:

  • Literature review of clinical trials and research in SCLC.
  • Analysis of chemotherapy and radiotherapy treatment outcomes.

Main Results:

  • Etoposide and cisplatin remain the standard chemotherapy for both limited and extensive stage SCLC.
  • Radiotherapy innovations, including thoracic irradiation and prophylactic cranial irradiation, have shown paradoxical advances for limited-stage SCLC.

Conclusions:

  • Further clinical and basic research is urgently needed for SCLC.
  • Radiotherapy innovations represent a promising avenue for improving outcomes in limited-stage SCLC.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...